Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
- The title of this article should be bk-MBDB. The initial letter is capitalized due to technical restrictions.
|CAS Registry Number||17762-90-2|
bk-MBDB a.k.a. butyl(one) is a psychedelic hallucinogenic drug first synthesized by Koeppe, Ludwig and Zeile and mentioned in their 1967 paper. It remained an obscure product of academia until 2005 when it was synthesized by a chemical supply company. It has since been explored as a possible entheogen. The full name of the chemical is beta-keto-MBDB, and as the name suggests, it shares the same relationship to MBDB as MDMC does to MDMA. The dosage range is not fully understood but seems to be lower than for MBDB. No formal research has been done on this chemical, and nothing is known of its pharmacological profile or toxicology, although anecdotal reports indicate it is subjectively similar to but milder than methylone.
When it first was available, the alternate names butylone and mebylone were proposed. These were abandoned because Butylone was found to be a trademarked name for pentobarbital, and mebylone because it was phonetically too easy to confuse with methylone and because it did not really reflect the chemical's structure.
It should be noted that bk-MBDB shares structural similarities to LSD, particularly in the ethylamine side chain and the amine side structure (the double bonded oxygen). In LSD, this side structure was explored by its creator Albert Hofmann because of its structural similarity to nicotinic acid diethylamine. Hoffman was hoping to create an oxytocic drug. It may be possible that by replacing the position of the Nitrogen-Hydrogen bond on the methyl side structure, and replacing it with carbon (thereby creating a diethylamide chain) that this drug will gain significant psychedelic properties.
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|